Cytokinetics/CYTK

$67.55

0.82%
-
1D1W1MYTD1YMAX

About Cytokinetics

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.

Ticker

CYTK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Blum

Employees

423

Headquarters

South san francisco, United States

Cytokinetics Metrics

BasicAdvanced
$7.1B
Market cap
-
P/E ratio
-$5.45
EPS
0.69
Beta
-
Dividend rate
$7.1B
0.69373
$110.25
$25.98
2.13M
6.117
-16.52%
-57.23%
-63.72%
943.407
-92.04%
-28.22%
-48.72%

What the Analysts think about Cytokinetics

Analyst Ratings

Majority rating from 19 analysts.
Buy

Price Targets

Average projection from 17 analysts.
40.73% upside
High $122.00
Low $60.00
$67.55
Current price
$95.06
Average price target

Cytokinetics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-8,550% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.6M
433.33%
Net income
$-136.8M
5.72%
Profit margin
-8,550%
-80.18%

Cytokinetics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 42.18%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.38
-$1.34
-$1.35
-$1.38
-
Expected
-$1.20
-$1.15
-$0.74
-$0.97
-$1.14
Surprise
15.07%
16.93%
81.86%
42.18%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cytokinetics stock?

Cytokinetics (CYTK) has a market cap of $7.01B as of April 21, 2024.

What is the P/E ratio for Cytokinetics stock?

The price to earnings (P/E) ratio for Cytokinetics (CYTK) stock is 0 as of April 21, 2024.

Does Cytokinetics stock pay dividends?

No, Cytokinetics (CYTK) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next Cytokinetics dividend payment date?

Cytokinetics (CYTK) stock does not pay dividends to its shareholders.

What is the beta indicator for Cytokinetics?

Cytokinetics (CYTK) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Cytokinetics stock price target?

The target price for Cytokinetics (CYTK) stock is $95.06, which is 40.73% above the current price of $67.55. This is an average based on projections from 17 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cytokinetics stock

Buy or sell Cytokinetics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing